Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452283
Status:
COMPLETED
Last Update Posted:
2013-01-31
First Post:
2007-03-23
Brief Title:
Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy
Sponsor:
University of Colorado Denver
Organization:
University of Colorado Denver
Study Overview
Official Title:
The Effect of a Systemic Non-selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve Pulmonary hypertension PHis a disease characterized by low oxygen levels in the blood and altered blood circulation The decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layerNFLin the retina and the resulting visual field compromise This situation is characteristic of glaucoma The ability to identify NFL thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss
We hypothesize that the rate of structural damage to the NFL a feature of glaucoma is higher in patients with PH than expected in healthy populations lacking this disease
We hypothesize that the rate of structural damage to the NFL a feature of glaucoma is higher in patients with PH than expected in healthy populations lacking this disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None